RSS
pre-clinical data
Preclinical data shows promise for potential treatment of chronic lymphocytic leukaemia
Private therapeutics company, Inflection Biosciences, has published preclinical data, demonstrating that its dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise for the treatment of chronic lymphocytic leukaemia (CLL). Read more
PLX cells shown to inhibit cancer cell growth in peer-reviewed article
Developer of placenta-based cell therapy products, Pluristem Therapeutics, has revealed that its PLX cells have been shown to significantly inhibit cancer cell growth in a recently published peer-reviewed article. Read more
Pre-clinical data of dual-targeting CAR therapy for multiple myeloma published
Clinical-stage biopharmaceutical company, Autolus, has announced the publication of pre-clinical data of a novel, dual-targeted, proliferating-inducing ligand (APRIL) chimeric antigen receptor (CAR) for the treatment of multiple myeloma. Read more
